PMID- 32203892
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20210126
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 126
DP  - 2020 Jun
TI  - Anti-hepatofibrotic effects of CGX, a standardized herbal formula: A multicenter 
      randomized clinical trial.
PG  - 110105
LID - S0753-3322(20)30297-3 [pii]
LID - 10.1016/j.biopha.2020.110105 [doi]
AB  - BACKGROUND: Chunggan extract (CGX) is an herbal formula used for the treatment of 
      chronic liver disease in traditional Korean medicine. Many preclinical studies 
      have suggested its therapeutic or preventive effects on liver fibrosis. To 
      evaluate the efficacy and safety of CGX, we conducted a randomized controlled 
      clinical trial of CGX in patients with liver fibrosis diagnosed by Fibroscan. 
      METHODS: We enrolled 67 subjects at two hospitals with chronic liver disorders 
      with a 5.5 </= liver stiffness measurement (LSM) score </= 16 kPa. Subjects were 
      randomly assigned at a 1:1:1 ratio with stratification (with/without concomitant 
      use of antivirals) and orally administered CGX (1 g or 2 g) or placebo twice 
      daily for 24 weeks. The end point was the change in instantaneous elasticity of 
      the liver assessed by Fibroscan before and after treatment. RESULTS: LSM scores 
      were significantly decreased in both the CGX1 g (2.5 +/- 1.7 kPa, p < 0.01) and 
      CGX2 g (1.9 +/- 2.0 kPa, p < 0.05) groups compared to the placebo (0.6 +/- 1.6 kPa) 
      group. The change was also significant in 35 subjects without concomitant use of 
      antiviral agents in the CGX1 g group (placebo 0.1 +/- 1.4 kPa vs. 2.7 +/- 1.6 kPa, p 
      < 0.01) but not in those with concomitant antiviral use (p > 0.05). No notable 
      adverse events were present. CONCLUSION: CGX appeared to have a pharmacological 
      effect against liver fibrosis. Further studies to confirm the results are needed 
      in the future using a larger sample size.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Joung, Jin-Yong
AU  - Joung JY
AD  - Liver and Immunology Research Center, Dunsan Oriental Hospital of Daejeon 
      University, 35353, Daedukdae-ro 176 bun-gil 75, Seo-gu, Daejeon, Republic of 
      Korea.
FAU - Kim, Hyeong-Geug
AU  - Kim HG
AD  - Liver and Immunology Research Center, Dunsan Oriental Hospital of Daejeon 
      University, 35353, Daedukdae-ro 176 bun-gil 75, Seo-gu, Daejeon, Republic of 
      Korea.
FAU - Lee, Jin-Seok
AU  - Lee JS
AD  - Liver and Immunology Research Center, Dunsan Oriental Hospital of Daejeon 
      University, 35353, Daedukdae-ro 176 bun-gil 75, Seo-gu, Daejeon, Republic of 
      Korea.
FAU - Cho, Jung-Hyo
AU  - Cho JH
AD  - Liver and Immunology Research Center, Dunsan Oriental Hospital of Daejeon 
      University, 35353, Daedukdae-ro 176 bun-gil 75, Seo-gu, Daejeon, Republic of 
      Korea.
FAU - Ahn, Yo-Chan
AU  - Ahn YC
AD  - Department of Health Service Management, Daejeon University, 96-3 Yongun-dong, 
      Dong-gu, Daejeon, 34520, Republic of Korea.
FAU - Lee, Dong-Soo
AU  - Lee DS
AD  - Department of Internal Medicine, Daejeon St. Mary's Hospital, College of 
      Medicine, The Catholic University of Korea, 64, Daeheung-ro, Jung-gu, Daejeon, 
      34943, Republic of Korea. Electronic address: endoscope@hanmail.net.
FAU - Son, Chang-Gue
AU  - Son CG
AD  - Liver and Immunology Research Center, Dunsan Oriental Hospital of Daejeon 
      University, 35353, Daedukdae-ro 176 bun-gil 75, Seo-gu, Daejeon, Republic of 
      Korea. Electronic address: ckson@dju.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20200320
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (chunggan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Case-Control Studies
MH  - Chromatography, High Pressure Liquid
MH  - Drug Monitoring
MH  - Drugs, Chinese Herbal/*pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Liver Cirrhosis/*drug therapy/etiology/pathology
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
OTO - NOTNLM
OT  - CGX
OT  - Fibroscan
OT  - Herbal medicine
OT  - Liver cirrhosis
OT  - Liver fibrosis
COIS- Declaration of Competing Interest The authors declare that they have no conflicts 
      of interest.
EDAT- 2020/03/24 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/03/24 06:00
PHST- 2020/02/20 00:00 [received]
PHST- 2020/03/10 00:00 [revised]
PHST- 2020/03/11 00:00 [accepted]
PHST- 2020/03/24 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
PHST- 2020/03/24 06:00 [entrez]
AID - S0753-3322(20)30297-3 [pii]
AID - 10.1016/j.biopha.2020.110105 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2020 Jun;126:110105. doi: 10.1016/j.biopha.2020.110105. Epub 
      2020 Mar 20.